Mesoblast Inc. (NASDAQ: MESO) is up sharply by 27.23% in pre-market trading on Friday, July 18, 2025, rising to $15.70 from its previous close of $12.34.
The surge follows the company’s report of US$13.2 million in gross revenue from Ryoncil® (remestemcel-L-rknd) sales during the first quarter after its product launch. Ryoncil® is notable as the first and only FDA-approved mesenchymal stromal cell (MSC) product available in the United States.
